Chris Bond, PhD, on Allogeneic and Induced Pluripotent Stem Cell Approaches to Cell Therapy


The senior vice president of Research & Early Development at Notch Therapeutics discussed the company’s approach to overcoming the drawbacks of autologous cell therapies.

“We wouldn't be here, if it wasn't for autologous therapy.... But there's significant challenges with that. This is personalized medicine. Scalability is a huge issue. Patients have to be leukapheresed, the manufacturing time is non-trivial, [with] times between 20 and 40 days. Those patients can progress before they receive the therapy... And when [manufacturing] fails, that patient doesn't receive what could potentially be a life-saving therapy. Fundamentally, I think we owe it to patients to figure out how to make sure that more patients get access, and sooner, both in lines of therapy, but also at point of diagnosis rather than at point of manufacture.”

While autologous approaches paved the way for cell therapy and have helped many patients in both clinical and commercial settings, they continue to have several important drawbacks, including their lengthy manufacturing time and limited scalability.

CGTLive spoke with Chris Bond, PhD, senior vice president of Research & Early Development, Notch Therapeutics, at the 7th Annual CAR-TCR Summit, held September 19-22, 2022, in Boston, Massachusetts, about the company’s decision to focus on allogeneic approaches to cell therapy and to base their therapies on induced pluripotent stem cells. Bond discussed the company's history and their efforts to overcome difficulties using notch signaling.

Afterwards, he discussed the company’s Engineered Thymic Niche (ETN) technology platform and how it is utilized to address challenges with scaling for production. Bond also spoke about Notch Therapeutics’ collaboration with Allogene Therapeutics, as well as the company’s focus on hematological malignancies and solid tumors as cell therapy targets. He noted that both chimeric antigen receptor T-cell (CAR-T) therapy and T-cell receptor (TCR) therapy options are being considered for solid tumors.

Recent Videos
Manali Kamdar, MD, on Liso-Cel's Ongoing Benefit in the Treatment Lanscape for LBCL
Steve Kanner, PhD, the chief scientific officer of Caribou Biosciences
David Dimmock, MBBS, on AI-Guided ASO Development for Ultra-Rare Diseases
Manali Kamdar, MD, on The Importance of Bringing Liso-Cel to Earlier Lines of Lymphoma Treatment
Subhash Tripathi, PhD, on Generating In Vivo CARs With A2-CAR-CISC EngTreg Cells
Luke Roberts, MBBS, PhD, on Challenges in Developing Gene Therapy for Heart Failure
Steve Kanner, PhD, the chief scientific officer of Caribou Biosciences
Paul Y. Song, MD, the chairman and chief executive officer of NKGen
Lisa Nieland on Slowing Tumor Growth in Glioblastoma With Novel AAV Therapy
Manali Kamdar, MD, on Acclimating to Routine CAR T Practice in the Field
© 2024 MJH Life Sciences

All rights reserved.